The 15th PSOGI International Congress on Peritoneal Surface Malignancies

Barcelona 2025

October 29th • 31st, 2025

Peritoneal Surface Oncology Group International

Organized by:

SEOQ Sociedad Española de Oncología Quirúrgica

GECOP Grupo Español de Cirugía Oncológica Peritoneal

Venue:

Fira Barcelona


CONGRESS CHAIRS

Dr. Fernando Pereira
Madrid, Spain

Dr. Pedro Bretcha-Boix
Alicante, Spain

Congress Announcement

"From small beginnings to Global Force"



With the collaboration of:

ISSPP

European Society of Coloproctology

ESGO European Society of Gynaecological Oncology

esso The European Society of Surgical Oncology Endorsed

Endorsed by:

AEC Asociación Española de Cirujanos

An educational activity of:

PSOGI esso European School of Peritoneal Surface Oncology

https://psogicongress2025.com

RanD

THE WORLD'S FIRST HIPEC SYSTEM PROVIDER

THERE MUST BE A REASON



Scientific and Organizing Committee

Luis Gonzalez-Bayón, *Surgical Oncology (Madrid, Spain)*
Lana Bijelic, *Surgical Oncology (Barcelona, Spain)*
Santiago González-Moreno, *Surgical Oncology (Madrid, Spain)*
Álvaro Arjona, *Surgical Oncology (Córdoba, Spain)*
Pedro Cascales, *Surgical Oncology (Murcia, Spain)*
Jorge Barriuso, *Medical Oncology (Madrid, Spain)*
Frederic Bibeau, *Pathology (Besançon, France)*
Max Lahaye, *Radiology (Amsterdam, The Netherlands)*

PSOGI Board

Paul H. Sugarbaker - *Washington (USA)*
Aditi Bhatt - *Bangalore (India)*
S.P. Somashekhar - *Bangalore (India)*
David L. Bartlett - *Pittsburgh, Pa (USA)*
Marcello Deraco – *Milano (Italy)*
Olivier Glehen - *Lyon (France)*
Diane Goéré - *Paris (France)*
Santiago González-Moreno - *Madrid (Spain)*
Ignace de Hingh - *Eindhoven (The Netherlands)*
Yan Li - *Beijing (China)*
Brendan John Moran - *Basingstoke (United Kingdom)*
David Morris - *Sydney (Australia)*
Aviram Nissan - *Tel Aviv (Israel)*
Pompiliu Piso - *Regensburg (Germany)*
Beate Rau - *Berlin (Germany)*
Vic Verwaal - *Lund (Sweden)*
Yutaka Yonemura - *Kyoto (Japan)*
Claudio Quadros - *Salvador Bahía (Brasil)*
Paolo Sammartino - *Rome (Italy)*

Pre-Congress Course
Peritoneal Surface Malignancy Video Workshop and Live Surgery

08.30-17.00 Tuesday, October 28th, 2025
CHU Moisés Broggi. Barcelona, Spain

Program at a glance		
October 29th	**Main room**	**Parallel room**
8.00	Registration	Meet the expert breakfast: best practices in colorectal peritoneal metastases
8.30	Congress opening	
9.00 - 10.30	Controversies in PMP and appendix neoplasms	Abstracts session (9 selected)
10.30 - 11.00	**Coffee break**	
11.00 - 12.30	Joint PSOGI-ESCP symposium. Beyond standards in colorectal metastases	PERMITT position in ongoing clinical trials
12.30 - 13.30	PRO/CON Session: PIPAC offers a meaningful advance in the management of unresectable peritoneal metastases	Young surgeons in PSM symposium
13.30 - 15.00	**Lunch**	
15.00 - 16.30	Most expected clinical trials on PSM	Abstracts session (9 selected)
16.30 - 17.00	**Coffee break**	
17.00 - 18.00	ISSPP session: Basic & Translational research in PSM	Alternatives to HIPEC in intraperitoneal therapy
18.00 - 18.30	Keynote lecture: can perioperative treatments preserve the surgical complete response obtained by the cytoreductive surgery?	
18.30 - 19.30	Advanced surgical techniques in peritoneal surface malignancies	Abstracts session (6 selected)
19.30	**End of the day and welcome drink**	

October 30th	Main room	Parallel room
8.00 - 9.00		Meet the expert Breakfast. From pixels to plan: Imaging peritoneal metastases for surgical strategy
09.00 -10.30	Neoadjuvant therapy in peritoneal surface malignancies	Abstracts Session (9 selected)
10.30 - 11.00	**Coffee break**	
11.00 - 12.30	Joint PSOGI-ESGO Symposium: Updates on gynecologic malignancies with peritoneal metastases	See it before you cut it: Preoperative CT/MRI of peritoneal disease
12.30 - 13.30	PRO/CON session. Cytoreductive surgery with HIPEC is a viable treatment option for patients with low volume peritoneal metastases of pancreatic cancer	**12.30 - 13.00:** Rationale of combined intraperitoneal and systemic treatment in gastric cancer peritoneal metastases (enhancing neoadjuvant treatment in gastric cancer) **13.00 - 13.30:** Peritoneal mesothelioma: Is there a room for further improvement in outcomes beyond CRS and HIPEC?
13.30 - 15.00	**Lunch**	
15.00 - 16.30	Minimally invasive surgery in peritoneal carcinomatosis	**15.00-16.00:** Tumor Board **16.00-16.30:** Oncologic hyperthermia: Clinical applications
16.30 - 17.00	**Coffee break**	
17.00 - 18.00	ISSPP session. Goals, expectations and outcomes of PM management in the young and the elderly – How do they differ?	Patient advocacy session
18.00 - 18.30	Keynote Lecture: Effective treatment of peritoneal carcinomatosis with carcinoembryonic antigen-directed CAR-T cells in a phase I/II trial	
18.30 - 19.30	Award session: Giants in PSM	
19.30	**End of the day and social dinner at 21.00 H**	

October 31th	Main room	Parallel room
8.00 - 9.00		Meet the expert Breakfast. *Pseudomyxoma peritonei:* Clarification about terminology and updates
9.00 - 10.30	Challenges in peritoneal surface malignancies. A researcher perspective	Best selected abstracts (6 selected)
10.30 - 11.00	**Coffee break**	
11.30 - 12.00	The peritoneal/plasmatic membrane. Is it overrated?	**11.00 - 12.30:** ISSPP session. Pre-habilitation i n high-complexity oncological surgery: Best practices and future perspectives
12.00 - 13.30	PSOGI historical consensus in PSM: A track record	**12.30 - 13.30:** Video Session (6 selected)
13.30	**Congress closure with announcement of PSOGI-2027**	

CAPNOPHARM



Pioneering the future of PIPAC

Meet us at PSOGI 2025 (Barcelona) 29th - 31st October – Stand 18

Wednesday, October 29th 2025

08.00 **Registration**

Main room

08.30 **Congress opening**

09.00-10.30 **Controversies in PMP and appendix neoplasms**
Moderators:
Luis González Bayón. *Hospital General Universitario Gregorio Marañón. Madrid, Spain*
Frèdèric Bibeau. *Centre Hospitalier Universitaire de Besançon. Marie et Louis Pasteur University. Besançon, France*

09.00-09.15 **New data about PMP and HAMN**
Peggy Dartigues. *Institut Gustave Roussy. Villejuif, France*

09.15-09.30 **Prognosis of PMP carcinomatosis: How detect cases that will recur?**
Lorena Martin. *The Christie NHS Foundation Trust. Manchester, England*

09.30-09.45 **Two-stage surgery**
Francois Quenet. *Institut du Cancer Montpellier Val d'Aurelle. Montpellier, France*

09.45-10.00 **Management of recurrent PMP**
Shigeki Kusamura. *Fondazione IRCCS Istituto Tumori. Milano, Italy*

10.00-10.30 **Discussion**

10.30-11.00 **Coffee break** ● **Poster presentation** ● **See page 31**

11.00-12.30 **Joint PSOGI-ESCP Symposium. Beyond standards in colorectal metastases**
Moderators:
Pedro Bretcha-Boix. *Hospital Quirónsalud Torrevieja. Alicante, Spain*
Miguel Pera. *Hospital Clínic Barcelona. Barcelona, Spain*

11.00-11.15 **CRS and HIPEC in patients with synchronous extraperitoneal metastases. Indications, short-term and long-term outcomes**
Pieter Tanis. *Department of Surgery. Erasmus MC. Rotterdam, The Netherlands*

11.15-11.30 **Repeat CRS + HIPEC for colorectal peritoneal metastases. Indications, surgical and chemotherapy considerations**
Faheez Mohamed. *Peritoneal Malignancy Institute Basingstoke. Hampshire, England*

Wednesday, October 29th 2025

11.30-11.45	**The role of the tumor microenvironment in CRC peritoneal metastases: Prognostic and therapeutic implications** Jenniffer Linares. *Hospital del Mar. Barcelona, Spain*
11.45-12.30	**Discussion**
12.30-13.30	**PRO/CON session: PIPAC offers a meaningful advance in the management of unresectable peritoneal metastases. *Sponsored by:*** CAPNOPHARM **Moderator:** Mohammed Alyami. *King Khalid Hospital. Najran, Saudi Arabia*
12.30-12.50	**PRO** Vahan Kepenekian. *Hospices Civils de Lyon. Lyon, France*
12.50-13.10	**CON** Thomas Wirth. *Hannover Medical School. Hannover, Germany*
13.10-13.30	**Discussion**
13.30-15.00	**Lunch ● Poster presentation ● See page 31**
15.00-16.30	**Most expected clinical trials on PSM** **Moderators:** Beate Rau. *Charité - University of Berlin. Berlin, Germany* Jorge Barriuso. *Hospital Universitario 12 de Octubre. Madrid, Spain*
15.00-15.12	**CAIRO6** Ignace de Hingh. *Catharina Kanker Instituut. Eindhoven. North Brabant, The Netherlands*
15.12-15.24	**DISCO TRIAL** Max Lahaye. *The Netherlands Cancer Institute Antoni Van Leeuwenhoek. Amsterdam, The Netherlands*
15.24-15.36	**GASTRICHIP** Olivier Glehen. *Hôpital Lyon Sud. Université Claude Bernard Lyon. Pierre Bénite, France*
15.36-15.48	**GECOP-MMC.** Fernando Pereira. *Hospital Universitario de Fuenlabrada. Fuenlabrada, Madrid. Spain*
15.48-16.00	**PERISCOPE II** Judith SE Quik. *The Netherlands Cancer Institute Antoni Van Leeuwenhoek. Amsterdam, The Netherlands*
16.00-16.12	**PRECINCT** Aditi Bhatt. *Shalby Cancer and Research Institute. Ahmedabad, India*
16.12-16.30	**Discussion**
16.30-17.00	**Coffee break ● Poster presentation ● See page 32**

Wednesday, October 29th 2025

17.00-18.00 **ISSPP session: Basic & Translational research in PSM**
Chairs:
Wiebke Solass. *Universität Bern. Institut für Gewebemedizin und Pathologie (IGMP). Bern, Switzerland*
Frèdèric Bibeau. *Centre Hospitalier Universitaire de Besançon. Marie et Louis Pasteur University. Besançon, France*

17.00-17.15 **Organoids in peritoneal metastasis research?**
Onno Kranenburg. *Universitair Medisch Centrum Utrecht. Utrecht, The Netherlands*

17.15-17.30 **Macrophage mesothelium circuits in health and disease**
Joel Zindel. *Eidgenössische Technische Hochschule Zürich. Zürich, Switzerland*

17.30-17.45 **AI for diagnosing cancer: How does it work?**
Amjad Khan. *Institut für Gewebemedizin und Pathologie. Universität Bern. Bern, Switzerland*

17.45-18.00 **Discussion**

18.00-18.30 **Keynote Lecture: Can perioperative treatments preserve the surgical complete response obtained by the cytoreductive surgery? *Sponsored by:*** COMBAT MEDICAL
Moderator:
Fernando Pereira. *Hospital Universitario de Fuenlabrada. Fuenlabrada, Madrid. Spain*
Speaker:
Paul Sugarbaker. *Washington Cancer Institute. Washington D. C., USA*

18.30-19.30 **Advanced surgical techniques in peritoneal surface malignancies**
Moderators:
Rafael Morales. *Hospital Universitari Son Espases. Palma, Spain*
Aviram Nissan. *Ziv Medical Center. Sefad, Israel*

18.30-18.45 **How to tackle high volume diaphragmatic and perihepatic disease?**
Lana Bijelic. *Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona. Spain*

18.45-19.00 **Complex GI resection and reconstruction options in CRS: From gastrectomy to atypical colorectal anastomoses**
Olivier Glehen. *Hôpital Lyon Sud. Université Claude Bernard Lyon. Pierre Bénite, France*

19.00-19.15 **Management of thoracic recurrence of PMP and administration of HITHOC**
Faheez Mohamed. *Peritoneal Malignancy Institute Basingstoke. Hampshire, England*

19.15-19.30 **Recurrent pelvic malignancy: Strategies for complete resection and prevention of complications**
Niels Kok. *The Netherlands Cancer Institute Antoni van Leeuwenhoek. Amsterdam, The Netherlands*

19.30-19.45 **Discussion**

19.45-21.00 **End of the day and Welcome cocktail – FIRA BARCELONA**

Wednesday, October 29th 2025

08.00 **Registration**

Parallel room

08.00-09.00 **Meet the expert Breakfast. Best practices in colorectal peritoneal metastases**
Moderator: Francois Quenet. *Institut du Cancer Montpellier Val d'Aurelle. Montpellier, France*

09.00-10.30 **Abstracts Session (9 selected)**
Moderators:
César Pablo Ramírez. *Hospital Quirónsalud Málaga. Málaga, Spain*
Fernando Martínez Regueira. *Clínica Universidad de Navarra. Pamplona, Spain*

Combined nabpaclitaxel pressurized intraperitoneal aerosol chemotherapy with systemic nabpaclitaxel-gemcitabine chemotherapy for pancreatic cancer peritoneal metastases: The interim analysis of Nab-PIPAC trial
Andrea Di Girgio. *Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Rome, Italy*

The influence of synchronous or metachronous liver metastases on outcomes of patients with colorectal cancer peritoneal metastases
Marco Antonio Achurra Olmos. *Instituto Oncológico Nacional: ION. Panama, Panama*

Tailoring HIPEC with patient-derived organoids in colorectal peritoneal metastases. Results from the first stage of the prospective phase II organoHIPEC Clinical Trial (clinicaltrials.gov - NCT06057298)
Dario Carlo Angelo Baratti. *Fondazione IRCCS Istituto Nazionale dei Tumori. Milano, Italy*

Cost-effectiveness analysis of dedicated MR imaging versus surgical staging in patients with colorectal peritoneal metastases
Niels Kok. *The Netherlands Cancer Institute Antoni van Leeuwenhoek. Amsterdam, The Netherlands*

Superior surgical planning with 15-min delayed CT: precise preoperative evaluation and resectability prediction in pseudomyxoma peritonei
Nan Zhou. *Aerospace Center Hospital. Beijing, China*

National consensus on the definition of a textbook oncologic outcome (TOO) for cytoreductive surgery with HIPEC in peritoneal surface malignancies
Manuela Robella. *Candiolo Cancer Institute. FPO—IRCCS. Candiolo, Italy*

A radiomics-based interpretable model integrating delayed-phase CT and clinical features for predicting the pathological grade of appendiceal pseudomyxoma peritonei
Dong Bai. *Aerospace Center Hospital. Beijing, China*

Wednesday, October 29th 2025

All roads lead to Rome: Convergence of biological themes in tumour microenvironment using multiomics analysis unravelled new intraperitoneal therapeutic strategies for peritoneal metastases
Johnny Ong. *National Cancer Centre Singapore. Singapore*

Microbial signatures in pseudomyxoma peritonei: First evidence of mucus-producing bacteria and fungi in soft mucin
Antonio Romero. *Universidad de Córdoba. Córdoba, Spain*

10.30-11.00 **Coffee break ● Poster presentation ● See page 31**

11.00-12.30 **PERMITT position in ongoing clinical trials**
Moderators:
Olivia Sgarbura. *Institut du Cancer de Montpellier. Montpellier, France*
Álvaro Arjona-Sánchez. *Hospital Universitario Reina Sofía. Córdoba, Spain*

Colon

11.00-11.06 **FOXHIPECT4**
Álvaro Arjona-Sánchez. *Hospital Universitario Reina Sofía. Córdoba, Spain*

11.06-11.12 **INTERACT-PLUS**
Eva Madsen. *PhD of the Erasmus MC in Rotterdam, The Netherlands*

11.12-11.18 **OLIPEC**
J. B. Tuynman. *Amsterdam University Medical Center, Amsterdam. The Netherlands*

11.18-11.24 **IMPACT**
Mustafa Raoof. *City of Hope Cancer Center. Duarte, California. USA*

Gastric

11.24-11.30 **PREVENT (FLOT9)**
Pompiliu Piso. *Hospital Barmherzige Brüder. University of Regensburg. Regensburg, Germany*

11.30-11.36 **AXIRI**
Olivia Sgarbura. *Institut du Cancer de Montpellier. Montpellier, France*

11.36-11.42 **CONVERGENCE**
Olivier Glehen. *Hôpital Lyon Sud. Université Claude Bernard Lyon. Pierre Bénite, France*

Ovarian

11.42-11.48 **TORPEDO 2**
Aditi Bhatt. *Shalby Cancer and Research Institute. Ahmedabad, India*

Wednesday, October 29th 2025

11.48-11.54 **PROOV**
Willemien Van Driel. *Netherlands Cancer Institute Antoni Van Leeuwenhoek. Amsterdam, The Netherlands*

Appendix

11.54-12.00 **APPIPEC**
Peter Cashin. *Akademiska sjukhuset. Uppsala, Sweden*

12.00-12.30 **Discussion**

12.30-13.30 **Young surgeons in PSM Symposium**
Moderators:
Domenico Sabia. *Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona. Spain*
Vic Verwaal. *Skånes universitetssjukhus Lund. Lund, Sweden*

12.30-12.40 **What is special about teaching and learning PSM surgery?**
Vadim Gushchin. *Mercy Medical Center. Baltimore, Maryland. USA*

12.40-12.50 **How to become a PSM scientist?**
Kiran Turaga. *Yale Cancer Center. New Haven, Connecticut. USA*

12.50-13.20 **Pitch your trial idea: Mini-competition**
Moderators:
Olivia Sgarbura. *Institut du Cancer de Montpellier. Montpellier, France*
Kjersti Flatmark. *Oslo Universitetssykehus. Radiumhospitalet, Oslo. Norway*
Alexandra Gangi. *Cedars-Sinai Medical Center. Los Angeles, California. USA*

PREDICTORG – A Multicentre Prospective Translational Study investigating a Personalised Medicine Approach in the Management of Colorectal Peritoneal Metastatic Cancer
Anshini Jain. *Peter MacCallum Cancer Centre, Melbourne. Australia*

Impact of an OMega-3 Enriched Oral Nutritional Supplement on Improving Surgical Outcomes in Patients with Peritoneal Carcinomatosis Undergoing Cytoreductive Surgery: A Prospective, Randomized, Double-Blind Study.
Federica Ferracci. *Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome. Italy*

CAR T treatment targeting a glycosylated cancer specific epitope for mucinous peritoneal surfacemalignancies – a phase I trial
Malin Simlund. *Oslo University Hospital, Oslo. Norway*

Use of Artificial Intelligence in them easurement of peritoneal carcinomatosis - Evaluation of the Kappa Index
Ana Carolina Fleig. *Santa Casa Porto Alegre Hospital, Porto Alegre. Brazil*

Wednesday, October 29th 2025

Developing AI-based predictive Molecular And radiological markers to tailor Surgical approaches for peritoneal metastasis from COlorectal cancer (DAMASCO)
Gaia Colletti. *National Cancer Institute of Milan, Milan. Italy*

13.20-13.30 **Discussion**

13.30-15.00 **Lunch • Poster presentation • See page 31**

15.00-16.30 **Abstracts Session (9 selected)**
Moderators:
Vanessa Concepción Martín. *Hospital Universitario Nuestra Señora de Candelaria. Santa Cruz de Tenerife, Spain*
Israel Manzanedo. *Hospital Universitario de Fuenlabrada. Fuenlabrada, Madrid. Spain*

Beyond PCI score: How small bowel involvement shapes survival in malignant peritoneal mesothelioma
Alessandra Brescacin. *Istituto Nazionale Tumori. Milan, Italy*

Immunonutrition affects the preoperative proinflammatory status of patients with peritoneal carcinomatosis
Araceli Mateo Díaz. *Hospital General Universitario de Elche. Elche, Alicante*

Non-inferiority of simplified surgery for acellular mucin serosal deposition in pseudomyxoma peritonei: A multicenter prospective randomized controlled trial
Haipeng Zhou. *Aerospace Center Hospital. Beijing, China*

High-dose cisplatinum/doxorubicin/oxaliplatinum PIPAC for gastric colon appendix mesothelioma ovarian PC origin: A multicentric study of PSM-SICO (Italian Society of Surgical Oncology) – oncoTEAM purpose
Marco Vaira. *AOU Policlinico Di Modena. Modena, Italy*

Bidirectional treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy (PIPAC) and systemic chemotherapy: A systematic review
Manuela Robella. *Candiolo Cancer Institute. FPO – IRCCS. Candiolo, Italy*

Radiomics-clinical fusion model enhances detection of mesenteric contraction in pseudomyxoma peritonei
Dong Bai. *Aerospace Center Hospital. Beijing, China*

Associations between preoperative cardiopulmonary exercise testing variables and postoperative outcomes in patients with peritoneal malignancy undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Cherry Koh. *Royal Prince Alfred Hospital. The University of Sydney. Camperdown, Australia*

Wednesday, October 29th 2025

A radiomics-based prediction of overall survival in colorectal cancer patients with peritoneal metastases
QingFeng Lin. *Sun Yat-Sen University. Canton, China*

Insights into evolving practice outcomes and challenges: Seven years after the establishment of a state-wide highly specialized peritoneal malignancy service
Sascha Karunaratne. *Royal Prince Alfred Hospital. Camperdown, Australia*

16.30-17.00 **Coffee break ● Poster presentation ● See page 32**

17.00-18.30 **Alternatives to HIPEC in intraperitoneal therapy**
Moderators:
Pedro Cascales. *Hospital Clínico Universitario Virgen de la Arrixaca. Murcia, Spain*
Juan José Segura Sampedro. *Hospital Universitario La Paz. Madrid, Spain*

17.00-17.15 **Intraperitoneal oncolytic virotherapy as an alternative to HIPEC**
Can Yurttas. *Universitätsklinikum Tübingen.Tübingen, Germany*

17.15-17.30 **Hydrogel-based systems for intraperitoneal drug delivery in peritoneal carcinomatosis**
Juan José Segura-Sampedro. *Hospital Universitario La Paz. Madrid, Spain*

17.30-17.45 **Potential of nanosized therapeutics for intraperitoneal delivery**
Wim Ceelen. *Universitair Ziekenhuis Gent. Gent, Belgium*

17.45-18.00 **Current perspectives of CAR-T cells therapy in peritoneal carcinomatosis**
Siyuan Qian. *Hospital Universitario Fundación Jimenez Díaz. Madrid, Spain*

18.00-18.30 **Discussion**

18.30-19.30 **Abstracts Session (6 selected)**
Moderators:
Estibaliz Pérez-Viejo. *Hospital Universitario de Fuenlabrada. Fuenlabrada, Madrid. Spain*
Pedro Villarejo. *Hospital Universitario Fundación Jiménez Díaz. Madrid, Spain*

Harpsicle: a prospective observational study on HIPEC regimens in colorectal peritoneal metastases
Mufaddal Kazi. *Tata Memorial Hospital. Mumbai, India*

Preoperative chemotherapy cytoreductive surgery (CRS) and HIPEC in primary high-grade serous ovarian cancer with peritoneal metastases: focus on the number of cycles from PMS-SICO oncoTEAM
Gianmario Edoardo Poto. *University of Siena. Siena, Italy*

Wednesday, October 29th 2025

Optimizing preclinical models of peritoneal carcinomatosis in ovarian cancer to advance translational intraperitoneal therapies
M.ª Teresa Perelló Trias. *Universidad de las Islas Baleares (UIB). Palma, Spain*

Matrix-bound nanovesicles drive immune suppression in colorectal peritoneal metastases
Luca Varinelli. *Fondazione IRCCS Istituto Nazionale dei Tumori Milano. Milan, Italy*


Is there a delay in the initiation of adjuvant chemotherapy in patients undergoing cytoreductive surgery and HIPEC?
Cristina Pineño Flores. *Hospital Universitario Son Espases. Palma, Spain*

Cytoreductive surgery plus TKIs improves survival in peritoneal metastatic GISTS: A retrospective study
Huaiming Wang. *The Sixth Affiliated Hospital of Sun Yat-sen University. Guangdong Province, China*

19.30-21.00 **End of the day and Welcome cocktail – FIRA BARCELONA**

REGER medizintechnik

A New Dimension of Nebulization



NebuCore

Thursday, October 30th, 2025

Main room

09.00-10.30 **Neoadjuvant therapy in peritoneal surface malignancies**

Moderators:

Ignace de Hingh. *Catharina Kanker Instituut. Eindhoven. North Brabant, The Netherlands*

Vic Verwaal. *Skånes universitetssjukhus Lund. Lund, Sweden*

09.00-09.15 **Use or misuse of neoadjuvant systemic therapy in PSM (evidence and influence on surgical indications or decisions)**

Olivia Sgarbura. *Institut du Cancer de Montpellier. Montpellier, France*

09.15-09.30 **Assessment and prognostic value of pathologic response to neoadjuvant therapy**

Frèdèric Bibeau. *Centre Hospitalier Universitaire de Besançon. Marie et Louis Pasteur University. Besançon, France*

09.30-09.45 **Response assessment by imaging studies after neoadjuvant therapy in PSM**

Clarisse Dromain. *Centre Hospitalier Universitaire Vaudois. Lausanne, Switzerland*

09.45-10.00 **Surgical tips for cytoreductive surgery after neoadjuvant therapy in PSM (Does it change technique? What to resect?)**

Pompiliu Piso. *Hospital Barmherzige Brüder. University of Regensburg. Regensburg, Germany*

10.00-10.30 **Discussion**

10.30-11.00 **Coffee break** • **Poster presentation** • **See page 33**

11.00-12.30 **Joint PSOGI-ESGO Symposium: Updates on gynecologic malignancies with peritoneal metastases.** ***Sponsored by:*** RAND

Moderators:

Pedro Cascales. *Universidad de Murcia. Hospital Clínico Universitario Virgen de la Arrixaca. Murcia, Spain*

Jordi Ponce Sebastià. *Hospital Universitari de Bellvitge. L´Hospitalet de Llobregat, Barcelona. Spain*

11.00-11.15 **An update on treatment of peritoneal metastasis of endometrial cancer and rare histologies of epithelial ovarian cancer (clear cell, mucinous adenocarcinoma, carcinosarcoma)**

Álvaro Tejerizo. *Hospital Universitario 12 de Octubre. Madrid, Spain*

11.15-11.30 **Less is more or more is more? Surgical decision-making during interval cytoreduction of ovarian cancer treated with neoadjuvant chemotherapy**

Nikolaos Thomakos. *"Alexandra" Hospital. National and Kapodistrian University of Athens. Athens, Greece*

Thursday, October 30th, 2025

11.30-11.45 **Does PIPAC have a role in the management of recurrent, unresectable peritoneal metastases of ovarian cancer?**
Thanh Dellinger. *City of Hope Comprehensive Cancer Center. Duarte, California. USA*

11.45-12.00 **When and how to surgically treat recurrent ovarian cancer? From selection criteria to use of HIPEC**
Jean Marc Classe. *Institut de Cancérologie de l'Ouest, Nantes, France*

12.00-12.30 **Discussion**

12.30-13.30 **PRO/CON session: Cytoreductive surgery with HIPEC is a viable treatment option for patients with low volume peritoneal metastases of pancreatic cancer**
Moderator:
Pompiliu Piso. *Hospital Barmherzige Brüder. University of Regensburg. Regensburg, Germany*

12.30-12.50 **PRO**
Travis Grotz. *Mayo Clinic. Rochester, Minnesota. USA*

12.50-13.10 **CON**
Teresa Macarulla. *Hospital Universitari Vall d´Hebron. Barcelona, Spain*

13.10-13.30 **Discussion**

13.30-15.00 **Lunch ● Poster presentation ● See page 33**

15.00-16.30 **Minimally invasive surgery in peritoneal carcinomatosis**
Moderators:
Aditi Bhatt. *Shalby Cancer and Research Institute. Ahmedabad, India*
S.P Somashekhar. *International Institute of Oncology. Bangalore, India*

15.00-15.15 **Minimally invasive approach for abdomen exploration, how to discover the hidden disease**
Antonio Sommariva. *Istituto Oncologico Veneto IRCCS. Padova, Veneto. Italy*

15.15-15.30 **Robot assisted minimally invasive cytoreductive surgery. Is it the robot a good alternative?**
Mohammed Alyami. *King Khalid Hospital. Najran, Saudi Arabia*

15.30-15.45 **Minimally invasive approach for pelvic disease, tricks and tips**
S.P Somashekhar. *International Institute of Oncology. Bangalore, India*

15.45-16.00 **Barcelona Consensus in minimally invasive approach for peritoneal carcinomatosis**
Álvaro Arjona-Sánchez. *Hospital Universitario Reina Sofía. Córdoba, Spain*

16.00-16.30 **Discussion**

16.30-17.00 **Coffee break ● Poster presentation ● See page 34**

Thursday, October 30th, 2025

17.00-18.00 **ISSPP session: Goals, expectations and outcomes of PSM management in the young and the elderly – How do they differ?**
Moderators:
Martin Hübner. *Centre Hospitalier Universitaire Vaudois. Lausanne, Switzerland*
Lana Bijelic. *Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona. Spain*

17.00-17.10 **Adaptations of perioperative care in the elderly**
Safak Gül-Klein. *Charité-Universitätsmedizin Berlin. Surgical Clinic. Berlin, Germany*

17.10-17.20 **Limited indications for CRS/HIPEC in older patients**
Vahan Kepenekian. *Hospices Civils de Lyon. Lyon, France*

17.20-17.30 **Extended indications for CRS/HIPEC in younger patients?**
Almog Ben-Yacoov. *Chaim Sheba Medical Center. Tel-Hashomer. Ramat-Gan, Israel*

17.30-17.40 **Current contraindications for PIPAC**
Olivia Sgarbura. *Institut du Cancer de Montpellier. Montpellier, France*

17.40-18.00 **Discussion**

18.00-18.30 **Keynote Lecture: Effective treatment of peritoneal carcinomatosis with carcinoembryonic antigen-directed CAR-T cells in a phase I/II trial**
Moderator:
Pedro Bretcha-Boix. *Hospital Quirónsalud Torrevieja. Alicante, Spain*
Speaker:
Siyuan Qian. *Hospital Universitario Fundación Jimenez Díaz. Madrid, Spain*

18.30-19.30 **Award session: Giants in PSM**
Interview: Paul Sugarbaker to Brendan Moran
Talk. Peritoneal Surface Oncology International: From small beginnings to Global Force by Brendan Moran. *Peritoneal Malignancy Institute Basingstoke. Hampshire, England*

19.30 **End of the day**

21.00 **Social dinner - CASA MORITZ**
Ronda Sant Antoni, 39 - 08011 Barcelona. ***Sponsored by:*** RAND

Thursday, October 30th, 2025

Parallel room

08.00-09.00 **Meet the expert Breakfast: From pixels to plan. Imaging peritoneal metastases for surgical strategy**

Moderator:

Max Lahaye. *The Netherlands Cancer Institute Antoni Van Leeuwenhoek. Amsterdam, The Netherlands*

09.00-10.30 **Abstracts Session (9 selected)**

Moderators:

Gloria Ortega-Pérez. *MD Anderson Cancer Center. Madrid – Hospiten. Madrid, Spain*

Francisco Javier Lacueva. *Universidad Miguel Hernández. Elche, Alicante. Spain*

Preoperative frailty predicts functional recovery and quality of life outcomes following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy

Daniel Steffens. *Royal Prince Alfred Hospital / The University of Sydney. Camperdown, Australia*

Hyperthermic intraperitoneal chemotherapy with cytoreductive surgery improves outcomes in advanced epithelial ovarian cancer across different settings: Experience from a tertiary oncology care center in India

Mukurdipi Ray. *All India Institute of Medical Sciences. Delhi, New Delhi. India*

Peritoneal Regression Grading Score (PRGS) improves survival prediction in patients with neoadjuvant chemotherapy for ovarian cancer

Flurina Saner. *Bern University Hospital. Bern, Switzerland*

Quality of life after complete cytoreduction for advanced ovarian carcinomatosis: First prospective experience from Morocco and Africa using the EORTC QLQ-OV28

Amine Souadka. *National Institute of Oncology Mohammed Vth University. Rabat, Morocco*

Extended surgery confers no survival benefit for low-grade appendiceal mucinous neoplasms (LAMN) with or without limited peritoneal spread: New evidence from a multicenter working group (LAMNET)

Marcello Guaglio. *IRCCS Istituto Nazionale dei Tumori. Milan, Italy*

Anesthesiologic survey on perioperative management of patients with peritoneal carcinomatosis treated by cytoreductive surgery + HIPEC on behalf of SICO (Italian Society of Surgical Oncology) – PSM oncoTEAM

Marco Vaira. *AOU Policlinico di Modena. Modena, Italy*

Does open versus closed HIPEC with mitomycin C affect cytopenia rates following cytoreductive surgery?

Prateek Arora. *The Christie NHS Foundation Trust. Manchester, England*

Thursday, October 30th, 2025

Overall survival post-secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent colorectal cancer with peritoneal metastases
Raymond Hayler. *St. George Hospital. London, England*

Systemic absorption of mitomycin C and cisplatin by healthcare workers participating in hyperthermic intraperitoneal chemotherapy (HIPEC) operations
Paula Marincola Smith. *MD Anderson Cancer Center. Houston, Texas. USA*

10.30-11.00 **Coffee break ● Poster presentation ● See page 33**

11.00-12.30 **See it before you cut it: Preoperative CT/MRI of peritoneal disease**
Moderators:
Clarisse Dromain. *Centre Hospitalier Universitaire Vaudois. Lausanne, Switzerland*
Diane Goere. *Hôpital Saint-Louis AP-HP. Paris, France*

11.00-11.20 **Imaging innovations for peritoneal disease: What surgeons and radiologists need to know**
Vincent Vandecaveye. *Universitair Ziekenhuis Leuven. Leuven, Belgium*

11.20-11.40 **From scans to scalpel: The (surgeon's) playbook for interpreting peritoneal imaging**
Max Lahaye. *The Netherlands Cancer Institute Antoni Van Leeuwenhoek. Amsterdam, The Netherlands*

11.40-12.00 **Interactive case-based discussion of CTs and MRIs**
Pascal Rousset. *Hôpital Lyon Sud. Lyon, France*

12.00-12.30 **Discussion**

12.30-13.00 **Rationale of combined intraperitoneal and systemic treatment in gastric cancer peritoneal metastases (enhancing neoadjuvant treatment in gastric cancer)**
Moderator: Pablo Lozano Lominchar. *Hospital General Universitario Gregorio Marañón. Madrid, Spain*
Speaker. Li Yan. *Tsinghua University School of Clinical Medicine. Beijing Tsinghua Changgung Hospital. Beijing, China*

13.00-13.30 **Peritoneal mesothelioma: Is there a room for further improvement in outcomes beyond CRS and HIPEC?**
Moderator: Pedro Bretcha-Boix. *Hospital Quirónsalud Torrevieja. Alicante, Spain*
Speaker. Marcello Deraco.*Fondazione IRCCS Istituto Nazionale dei Tumori. Milan, Italy*

13.30-15.00 **Lunch ● Poster presentation ● See page 33**

Thursday, October 30th, 2025

15.00-16.00 **Tumor Board**

Moderator: Pablo Lozano Lominchar. *Hospital General Universitario Gregorio Marañón. Madrid, Spain*

Speakers. Aviram Nissan. *Ziv Medical Center. Sefad, Israel*
Li Yan. *Tsinghua University School of Clinical Medicine. Beijing Tsinghua Changgung Hospital. Beijing, China*
Joana Vidal. *Hospital del Mar. Barcelona, Spain*
Diane Goere. *Hôpital Saint-Louis AP-HP. Paris, France*
Claudio Quadros. *Hospital São Rafael, Rede D'Or/São Luiz. Salvador, Brasil*

16.00-16.30 **Oncologic hyperthermia: Clinical applications**

Moderator: Juan José Segura-Sampedro. *Hospital Universitario La Paz. Madrid, Spain*

Speaker. Marina Arangüena. *Institut Català d'Oncologia. Hospital Duran i Reynals. Barcelona, Spain*

16.30-17.00 **Coffee break • Poster presentation •** **See page 34**

17.00-18.30 **Patient advocacy session**

Moderator:
José Manuel Abad. *Healthcare journalist, SEOQ. Madrid, Spain*

Co-moderator:
Sandra Lara de Liz. *Asociación Peritoneum. Barcelona, Spain*

Presentation of the International Barcelona Patient Manifesto

Patient Associations:

- ACPMP (United States)
- Pseudomyxoma Survivor (UK)
- PMP Pals (United States)
- AMARAPE (France)
- Mesothelioma UK (UK)
- PMP Contact Groep (The Netherlands)
- Asociación Peritoneum (Spain)

Panel Discussion: Reality and unmet needs of the patient with peritoneal malignancy. From diagnosis to treatment and beyond

- Santiago González-Moreno – *MD Anderson Cancer Center Madrid – Hospiten (Madrid, Spain)*
- Dr. Faheez Mohamed – *Peritoneal Malignancy Institute (Basingstoke, UK)*
- Rebecca Halstead – *Peritoneal Tumor Clinical Nurse (The Christie, UK)*
- Dr. Jula Veerapong – *UC San Diego Health (United States)*
- Jim Carroll – *ACPMP Board President (United States)*
- Tim Brill – *Pseudomyxoma Survivor Trustee (UK)*

Thursday, October 30th, 2025

- Adele Jasion – *PMP Pals President (United States)*
- Jeanne Nascas – *AMARAPE (France)*
- Kate Williams – *Mesothelioma UK (UK)*
- Sandra Lara de Liz – *Asociación Peritoneum President (Spain)*

18.30-19.30 **Award session (in Main room): Giants in PSM**
Interview: Paul Sugarbaker to Brendan Moran
Talk: Peritoneal Surface Oncology International: From small beginnings to Global Force by Brendan Moran. *Peritoneal Malignancy Institute Basingstoke. Hampshire, England*

19.30 **End of the day**

21.00 **Social dinner - CASA MORITZ**
Ronda Sant Antoni, 39 - 08011 Barcelona. ***Sponsored by:*** RAND

HYPERTHERMIA PUMP™

Safely Deliver Hyperthermic Therapy

ferrer

SAVING LIVES. TOGETHER.

INTRAPERITONEAL & INTRATHORACIC HYPERTHERMIA


HIGHLY EFFICIENT

100% ALUMINUM-FREE DISPOSABLES[1]

USER-FRIENDLY

COMPACT DESIGN

BELMONT® MEDICAL TECHNOLOGIES
Saving Lives. Together.



This product complies with the current legislation on medical devices.
This promotional material is intended exclusively for healthcare professionals.

Bibliography:
1. Use instructions for Hyperthermia PumpIFU available at the stand

CE 1434

BELMONT® MEDICAL TECHNOLOGIES
710 BOSTON ROAD
BILLERICA, MA 01821, USA
USA: +1.855.397.6367
WORLDWIDE: +1.978.663.2212
WWW.BELMONTMEDTECH.COM

Friday, October 31st 2025

Main room

09.00-10.30 **Challenges in peritoneal surface malignancies. A researcher perspective**
Moderators:
Jorge Barriuso. *Hospital Universitario 12 de Octubre. Madrid, Spain*
David Bartlett. *Allegheny Health Network (AHN). Pittsburgh, Pennsylvania. USA*

09.00-09.15 **A research framework for appendiceal tumours**
Andreana N. Holowatyj. *Vanderbilt University Medical Center. Vanderbilt-Ingram Cancer Center. Nashville, Tennessee. USA*

09.15-09.30 **Translational research in rare and complex tumours. Pseudomyxoma as a model**
Raghavendar Nagaraju. *Cancer Research UK National Biomarker Centre. The Christie NHS Foundation Trust. Manchester, England*

09.30-09.45 **What can we learn from clinical research in other rare tumours?**
Ángela Lamarca. *Hospital Universitario Fundación Jiménez Díaz. Madrid, Spain*

09.45-10.00 **Precision medicine in appendix tumours, a look into near future**
Jorge Barriuso. *Hospital Universitario 12 de Octubre. Madrid, Spain*

10.00-10.30 **Discussion**

10.30-11.00 **Coffee break • Poster presentation •** **See page 35**

11.00-12.00 **The peritoneal/plasmatic membrane. Is it overrated?**
Moderators:
Pedro Bretcha-Boix. *Hospital Quirónsalud Torrevieja. Alicante, Spain*
Luis González Bayón. *Hospital General Universitario Gregorio Marañón. Madrid, Spain*

11.00-11.15 **Do we really understand the peritoneal/plasmatic barrier? What can we learn from peritoneal dialysis?**
Alberto Ortiz. *Hospital Universitario Fundación Jiménez Díaz. Madrid, Spain*

11.15-11.30 **How to create a population model for the study of an intraperitoneal chemotherapeutic agent?**
Ricardo Nalda. *School of Pharmacy. Universidad Miguel Hernández. Elche, Alicante. España*

11.30-11.45 **Pharmacokinetic and dynamic aspects of the drugs used in HIPEC**
Kurt Van der Speeten. *Ziekenhuis Oost-Limburg. Genk, Belgium*

11.45-12.00 **Discussion**

Friday, October 31st 2025

12.00-13.30 **PSOGI historical consensus in PSM: A track record**
Moderators:
Santiago González-Moreno. *MD Anderson Cancer Center. Madrid – Hospiten. Madrid, Spain*
Marcello Deraco. *Fondazione IRCCS Istituto Nazionale dei Tumori. Milan, Italy*

12.00-12.15 **PSOGI Consensus or PMP pathology and associated appendiceal neoplasms (2016)**
Norman Carr. *University Hospital Southampton. Southampton, Hampshire. England*

12.15-12.30 **PSOGI Consensus on HIPEC Regimens (2022) and Cytoreduction (2024)**
Olivier Glehen. *Hôpital Lyon Sud. Université Claude Bernard Lyon. Pierre Bénite, France*

12.30-12.45 **PSOGI-ESGO Consensus on Cytoreductive Surgery (2025)**
Aditi Bhat. *Shalby Cancer and Research Institute. Ahmedabad, India*

12.45-13.00 **Multisociety Consensus on PSM**
Shigeki Kusamura. *Fondazione IRCCS Istituto Tumori. Milano, Italy*

13.00-13.30 **Discussion**

13.30 **CONGRESS CLOSURE with announcement of PSOGI-2027**

Friday, October 31st 2025

Parallel room

08.00-09.00 **Meet the expert Breakfast. Pseudomyxoma peritonei: Clarification about terminology and updates**

Moderators:

Peggy Dartigues. *Institut Gustave Roussy. Villejuif, France*

Kiran Turaga. *Yale Cancer Center. New Haven, Connecticut. USA*

09.00-10.30 **Best selected abstracts (6 selected)**

Moderators:

Paolo Sammartino. *Sapienza Università di Roma. Roma, Italy*

Beate Rau. *Charité – University of Berlin. Berlin, Germany*

Appendiceal and colorectal mucinous adenocarcinoma with peritoneal disseminations. An Italian multicenter comparative study

Dario Carlo Angelo Baratti. *Fondazione IRCCS Instituto Nazionale dei Tumori. Milan, Italy*

Appendiceal cohort analysis from the intraperitoneal chemotherapy after cytoreductive surgery for peritoneal metastasis (ICARUS) clinical trial

Georgios Karagkounis. *Memorial Sloan Kettering Cancer Center. New York, USA*

Morphology and inter-observer variation in peritoneal disease assessment among expert peritoneal malignancy surgeons – The Morpheus survey

Vivekanand Sharma. *Breach Candy Hospital Trust. Mumbai, India*

The prognosis of patients with peritoneal metastases of colorectal cancer undergoing CRS-HIPEC is determined by their mutational profile

Arend G. J. Aalbers. *Netherlands Cancer Institute. Amsterdam, The Netherlands*

Second and third look laparoscopy in pT4 colon cancer patients for early detection of peritoneal metastases: The COLOPEC 2 randomized multicentre trial

Julie Hamm. *Erasmus MC. Rotterdam, The Netherlands*

A deep-learning model to predict the completeness of cytoreductive surgery in colorectal cancer with peritoneal metastasis

QingFeng Lin. *Sun Yat-Sen University. Canton, China*

10.30-11.00 **Coffee break** ● **Poster presentation** ● **See page 35**

11.00-12.30 **ISSPP session. Pre-habilitation in high-complexity oncological surgery: Best practices and future perspectives**

Moderators:

Faheez Mohamed. *Peritoneal Malignancy Institute Basingstoke. Hampshire, England*

Delia Cortés Guiral. *Instituto Viamed de Oncología Quirúrgica Avanzada. Madrid, Spain*

Friday, October 31st 2025

11.00-11.15 **Evidence of the impact of pre-habilitation in cytoreductive surgery**
Mohammed Alyami. *King Khalid Hospital. Najran, Saudi Arabia*

11.15-11.30 **ERAS Guidelines for cytoreductive surgery with or without HIPEC**
Martin Hübner. *Centre Hospitalier Universitaire Vaudois. Lausanne, Switzerland*

11.30-11.45 **Physical exercise for the cancer patient. Accessibility through new technologies**
Omar Tayara. *Hospital Viamed Santa Elena. Instituto Viamed Oncología Quirúrgica Avanzada (IVOQA). Madrid, Spain*

11.45-12.00 **Multidisciplinary Round Table. How to implement ERAS Guidelines in my center?**
All the panel
Irela López-Cobos. *Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí. Barcelona, Spain.*

12.00-12.30 **Discussion**

12.30-13.30 **Video Session (6 selected)**
Moderators:
Estibaliz Pérez Viejo. *Hospital Universitario de Fuenlabrada. Fuenlabrada, Madrid. Spain*
Ángel Serrano. *Hospital Universitario de Fuenlabrada. Fuenlabrada, Madrid. Spain*

A novel robotic approach to parietal peritonectomy in the management of peritoneal surface malignancies
Paolo Gaffuri. *EOC. Bellinzona, Switzerland*

The pelvic *cul de sac*
Joseph El-Sheikha. *Radiology. Peritoneal Malignancy Institute Basingstoke. Hampshire, England*

Cytoreduction of perihepatic spaces – Tips for achieving optimal cytoreduction in high volume disease
Domenico Sabia. *Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona. Spain*

Step-by-step surgical technique for cytoreductive surgery in a patient with pseudomyxoma peritonei
Woo Ram Kim. *Gangnam Severance Hospital, Yonsei Univerisity College of Medicine. Seoul, South Korea*

Retroperitoneal approach to laparoscopic cytoreduction
Vivek Sukumar. *Specialty Surgical Oncology Cancer Centre. Mumbai, India*

Laparo-robotic conversion surgery for limited peritoneal carcinomatosis in gastric cancer: Is there any space for a minimally invasive approach?
Jacopo Viganò. *Fondazione IRCCS Policlinico San Matteo. Pavia, italy*

13.30 **CONGRESS CLOSURE with announcement of PSOGI-2027 (Main room)**

FLEXIPER™

SYSTEM FOR INTRAOPERATIVE CHEMOHYPERTHERMIA



Wide **range of procedures**:

- HIPEC
- HITHOC
- ILP

Easy to use.
The 15.6" auxiliary display guides you through the steps.

The established **external heat exchanger** enables the solution to quickly reach the desired temperature.

Easy to move and transport.

MEDICA
SEAMLESS INNOVATION FOR LIFE QUALITY

www.medica-spa.com
info@medica-spa.com

Wednesday, October 29th 2025

10:30-11:00 **Morning coffee break**

Moderator: Estibaliz Pérez Viejo. *Hospital Universitario de Fuenlabrada. Fuenlabrada, Madrid. Spain*

Preliminary data on the recurrence patterns and treatment of colorectal cancer after crs-hipec: a dutch national retrospective cohort study. **Speaker:** Mitchell Emmers. *(The Netherlands)*

Follow up of low grade appendiceal mucinous neoplasms and the development of pseudomyxoma peritonei. **Speaker:** Vasanth Mark Samuel. *(United Kingdom)*

Accuracy of surgical pci and prognostic impact of pathologic pci in patients undergoingcytoreductive surgery for primary ovarian peritoneal metastasis. **Speaker:** Charif Khaled. *(Belgium)*

Staging laparoscopy before neoadjuvant chemotherapy for advanced ovarian cancer can it guide the extent of peritonectomy during interval cytoreductive surgery? **Speaker:** Deepti Mishra. *(India)*

13:30 - 15:00 **Lunch break**

Moderator: Vanessa Concepción Martín. *Hospital Universitario Nuestra Señora de Candelaria. Santa Cruz de Tenerife. Spain*

Challenges and coping mechanisms in patients and their caregivers following palliative gastrointestinal surgery for unresectable peritoneal metastases. **Speaker:** Schin Bek. *(Singapore)*

Impact of a prehabilitation program on physical conditioning prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. **Speaker:** Silvia Salvans. *(Spain)*

A theory to achieve cure for peritoneal metastases from low grade appendiceal mucinous carcinoma peritonei. **Speaker:** Yutaka Yonemura. *(Japan)*

Actual 8-year survival after crs-hipec for peritoneal metastasis of colorectal cancer suggests curation in one in five patients. **Speaker:** Lisa Magermans. *(The Netherlands)*

The good, the bad, and the ugly. a radiological pictorial review of appendieal malignancies. **Speaker:** Joseph El-Sheikha. *(United Kingdom)*

Ten-year of french multicentric experience in the management of gastric cancer with 79 347 patients. **Speaker:** Eveno Clarisse. *(Switzerland)*

Comparison of treatment outcomes between crs alone and crs plus hipec for appendiceal pseudomyxoma peritonei. **Speaker:** Hiroshi Takeuchi. *(Japan)*

Identification of peritoneal recurrence patterns following crs/hipec: a comparison of imaging, intraoperative findings, and initial tumor distribution. **Speaker:** Sarah Kalmbach. *(Germany)*

Wednesday, October 29th 2025

16:30-17:00 **Afternoon coffee break**

Moderator: Pedro Cascales. *Universidad de Murcia. Hospital Clínico Universitario Virgen de la Arrixaca. Murcia, Spain*

Evaluating the necessity of postoperative lower limb dopplers in patients undergoing cytoreductive surgery: a retrospective review. **Speaker:** Gemma Robbins. *(United Kingdom)*

Pushing the limits: crs and hipec for peritoneal metastases from hepatocellular carcinoma a systematic review. **Speaker:** Federica Ferracci. *(Italy)*

Comparative analysis of pipac nozzle designs: ex vivo evaluation of aerosol distribution, penetration and tissue concentration. **Speaker:** Mehdi Ouaissi. *(France)*

The perimmune project - a transcan-3 network intraperitoneal immune modulation for colorectal peritoneal metastases. **Speaker:** Annette Torgunrud. *(Norway)*

Thursday, October 30th, 2025

10:30-11:00 **Morning coffee break**

Moderator: Pablo Lozano. *Hospital General Universitario Gregorio Marañón. Madrid, Spain*

Cytoreductive surgery and hipec for primary treatment of ovarian cancer with peritoneal carcinomatosis. **Speaker:** Mar Vallés. *(Spain)*

Peritoneal metastases after curative treatment of esophageal cancer in a nationwide cohort: an overview of the incidence, risk factors, treatment and survival. **Speaker:** Ravi Seuter. *(The Netherlands)*

Effectiveness of a surgical lay health coach intervention on serious illness conversations in advanced cancer patients undergoing major elective surgery. **Speaker:** Hann Natalie Soh. *(Singapore)*

Concordance among radiological, laparoscopic and laparotomic peritoneal cancer index assessments in patients undergoing cytoreductive surgery for peritoneal metastases. **Speaker:** Silvia Guerrero Macías. *(Colombia)*

13:30-15:00 **Lunch break**

Moderator: Lorena Martín *The Christie NHS Foundation Trust. Manchester, England*

Comparison of hyperthermic chemotherapy and oncolytic virotherapy in in-vitro models of peritoneal surface malignancies. **Speaker:** Sophie Eliane Benezan. *(Germany)*

Development and validation of a prognostic model for high-grade appendiceal pseudomyxoma peritonei. **Speaker:** Ybin Fu. *(China)*

Patient-reported outcomes in malignant bowel obstruction: health-related quality of life as measured by md anderson gastrointestinal obstruction module. **Speaker:** Leng Khoong Lee. *(Singapore)*

Accuracy of surgical pci and prognostic impact of pathologic pci in patients undergoing cytoreductive surgery for primary colorectal cancer peritoneal metastasis. **Speaker:** Charif Khaled. *(Belgium)*

Development and validation of prognostic nomograms for overall survival in malignant peritoneal mesothelioma: a comparative analysis of traditional and machine learning models from the psogi/renape international cohort. **Speaker:** Shigeki Kusamura. *(Italy)*

Helicobacter pylori is prevalent in appendiceal cancer and predicts survival risk. **Speaker:** Hyun Young Park. *(United States)*

What is quality surgeon-patient communication in surgical oncology? a systematic review and qualitative synthesis. **Speaker:** Xiuting Jiang. *(Singapore)*

A world-first: integrating pre-admission psychological assessments as a routine component of care for peritoneal malignancy patients undergoing crs and hipec. evaluating the impact on patients. **Speaker:** Nancy Vanderpuye. *(United Kingdom)*

Thursday, October 30th, 2025

16:30-17:00 **Afternoon coffee break**

Moderator: César Pablo Ramírez. *Hospital Quirónsalud Málaga. Málaga, Spain*

Comparative oncological efficacy of chemotherapy, cytoreductive surgery with or without hipec in recurrent ovarian cancer: a network meta-analysis. **Speaker:** Richard Sassun. *(Italy)*

A novel multi-electrode electrostatic precipitation system for optimized intraperitoneal aerosolized drug delivery in a large animal model.**Speaker:** Mohammad Rahimi Gorji. *(Belgium)*

Non-invasive evaluation of pathologic response to neoadjuvant chemotherapy in non-mucinous peritoneal metastases and primary colorectal cancer using spectral dual-layer imaging. **Speaker:** Rémi Grange. *(France)*

B cell involvement in appendiceal cancer. **Speaker:** Hyun Young Park. *(United State)*

Friday, October 31st 2025

10:30-11:00 **Morning coffee break**


Moderator: Juan José Segura. *Hospital Universitario La Paz. Madrid, Spain*

Cytoreductive surgery with or without hipec after neoadjuvant chemotherapy in ovarian cancer: long term follow-up of the carcinohipec clinical trial. **Speaker:** Alida González Gil. *(Spain)*

Decision-making factors and post-surgical experiences for palliative gastrointestinal surgery among patients with peritoneal metastases: a qualitative analysis. **Speaker:** Swetha Mohan. *(Singapore)*

Functionalized porous carbon nanozyme for oxaliplatin sensitization in peritoneal metastases from colorectal cancer. **Speaker:** Rui Luo. *(China)*

Predictorg a multicentre personalised medicine approach in the management of colorectal peritoneal metastases. **Speaker:** Anshini Jain. *(Australia)*



▪ ACPMP/PMP PALS	10
▪ Asociación Peritoneum	8
▪ Capnopharm	18
▪ Combat Medical	2
▪ Corza	1
▪ Embiol	7
▪ Gamida	9
▪ Medica-Group	14
▪ Therma Solutions	3
▪ Rand	19
▪ Reger-Ferrer	13-15

Sponsors and collaborators

Diamond

RAND

Gold

CAPNOPHARM
Aerosol Chemotherapy Innovations

COMBAT MEDICAL

ThermaSolutions

Silver

REGER
medizintechnik

Bronze

corzamedical

emb
grupo

ferrer

GAMIDA
MOVING FURTHER IN HEALTHCARE

MEDICA
SEAMLESS INNOVATION FOR LIFE QUALITY

Collaborators

ACPMP
APPENDIX CANCER
PSEUDOMYXOMA PERITONEI
RESEARCH FOUNDATION

B BRAUN
SHARING EXPERTISE

cella

PMP PALS
NETWORK

European accreditation council on CME (EACCME®)

The **15th PSOGI International Congress on Peritoneal Surface Malignancies, Barcelona, Spain (October, 29th-31st, 2025),** has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **19.0** European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

ThermaSolutions

Global Leader in HIPEC and PIPAC





Technical Secretariat

Orense, n.º 11 • 4.ª planta
28020 Madrid
congreso3@grupoaran.com
congreso7@grupoaran.com
www.grupoaran.com

www.oncomedic.es/es/psogicongress2025